NEW YORK, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today announced the U.S. launch and commercial availability of clobetasol propionate ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Clobetasol propionate ophthalmic suspension 0.05% was ...

Please provide your email address to receive an email when new articles are posted on . Clobetasol propionate ophthalmic suspension 0.05% for postoperative inflammation and pain after ocular surgery ...

NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today congratulates Formosa Pharmaceuticals (TWO:6838) on the FDA approval of ...

Both coprimary endpoints were statistically significantly better in Clobetasol Propionate Ophthalmic Suspension 0.05%-treated patients compared with vehicle-treated patients. The Food and Drug ...

Clobetasol propionate ophthalmic suspension, 0.05% (APP13007) was approved by the U.S. Food and Drug Administration (FDA) in 2024. APP13007's active ingredient is the superpotent corticosteroid, ...

Taiwan-based Formosa Pharmaceuticals has entered into an exclusive licensing agreement with Apotex for exclusive rights in Mexico for the commercialization of clobetasol propionate ophthalmic ...

TAIPEI, Sept. 9, 2024 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (hereinafter referred to as "Formosa Pharma," 6838.TW) announced the successful first shipment to the United States of its new ...

TAIPEI, May 28, 2025 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced that the company has entered into an exclusive licensing agreement with Adalvo Limited ("Adalvo ...

Product-candidate would incorporate new steroid with the Optejet® for the millions of dry eye patients who experience periodic flare-ups NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc.